Chemed Corp. (CHE) Receives Consensus Recommendation of “Hold” from Brokerages

Chemed Corp. (NYSE:CHE) has earned an average rating of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $214.50.

A number of brokerages recently issued reports on CHE. Royal Bank Of Canada reiterated a “hold” rating and issued a $208.00 price objective on shares of Chemed Corp. in a report on Wednesday, July 5th. BidaskClub cut shares of Chemed Corp. from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 22nd. Oppenheimer Holdings, Inc. upped their price objective on shares of Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Finally, Zacks Investment Research upgraded shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price objective for the company in a report on Friday, July 28th.

In other Chemed Corp. news, insider Spencer S. Lee sold 1,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $197.46, for a total transaction of $197,460.00. Following the completion of the sale, the insider now directly owns 37,809 shares in the company, valued at $7,465,765.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Patrick P. Grace sold 500 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $201.48, for a total transaction of $100,740.00. Following the sale, the director now owns 4,515 shares of the company’s stock, valued at $909,682.20. The disclosure for this sale can be found here. Insiders have sold 16,500 shares of company stock valued at $3,315,600 over the last 90 days. Corporate insiders own 5.32% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Acrospire Investment Management LLC bought a new stake in Chemed Corp. during the second quarter valued at about $120,000. Pacad Investment Ltd. boosted its holdings in Chemed Corp. by 250.0% during the second quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after acquiring an additional 500 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Chemed Corp. by 12.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after acquiring an additional 83 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in Chemed Corp. during the second quarter valued at about $209,000. Finally, World Asset Management Inc bought a new stake in Chemed Corp. during the second quarter valued at about $216,000. Institutional investors own 96.96% of the company’s stock.

Shares of Chemed Corp. (NYSE:CHE) opened at 203.52 on Monday. The stock has a market cap of $3.25 billion, a P/E ratio of 50.49 and a beta of 1.13. The stock has a 50 day moving average price of $194.81 and a 200-day moving average price of $197.29. Chemed Corp. has a 12 month low of $132.92 and a 12 month high of $216.01.

Chemed Corp. (NYSE:CHE) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.89 by $0.26. The firm had revenue of $415.06 million during the quarter, compared to analysts’ expectations of $407.56 million. Chemed Corp. had a net margin of 4.16% and a return on equity of 26.18%. Chemed Corp.’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.80 earnings per share. On average, analysts forecast that Chemed Corp. will post $8.21 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Chemed Corp. (CHE) Receives Consensus Recommendation of “Hold” from Brokerages” was posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://baseballnewssource.com/markets/chemed-corp-che-receives-consensus-recommendation-of-hold-from-brokerages/1700357.html.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.